NCT02711319

Brief Summary

to optimize the functional outcome in early phase of gait rehabilitation in subacute incomplete SCI patients using rTMS as an additional treatment to physical therapy (e.g. to gait training in Lokomat®). Using this add-on therapeutic strategy, we expected larger improvement of gait function than with physical therapy alone.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Dec 2010

Longer than P75 for phase_3

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 17, 2016

Completed
Last Updated

March 17, 2016

Status Verified

February 1, 2016

Enrollment Period

4.5 years

First QC Date

March 9, 2016

Last Update Submit

March 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • ten-meters walking test (10MWT=Time in seconds to walk 10 meters.)

    Patients with or without orthesis were asked to walk at their fastest but most comfortable speed and step length and cadence assessed during the 10MWT (We added the number of steps taken in 10 m. Step length (meters)=distance (m) x 2 / number of stops (heel to heel of same foot). Cadence (steps/min.)=number of steps x 60 / time (seconds))

    Change from Baseline 10MWT at 4 and 8 weeks

Secondary Outcomes (3)

  • Modified Ashworth Scale (MAS)

    Change from Baseline MAS at 4 weeks

  • --Total motor score from upper (UEMS) and lower extremities (LEMS)

    Change from Baseline 1UEMS and LEMS at 4 and 8 weeks

  • Walking Index for SCI (WISCI) II

    Change from Baseline WISCI-II at 4 and 8 weeks

Study Arms (2)

active (real) rTMS (ACTIVE GROUP)

ACTIVE COMPARATOR

The patients were randomly distributed in two study groups: real or sham rTMS group. For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes.

Device: rTMS

sham rTMS (SHAM GROUP)

SHAM COMPARATOR

For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).

Device: sham rTMS

Interventions

rTMSDEVICE

For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes

Also known as: active rTMS, active group, real rTMS
active (real) rTMS (ACTIVE GROUP)
sham rTMSDEVICE

Sham Comparator: sham rTMS (SHAM GROUP) For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).

Also known as: sham group, placebo group
sham rTMS (SHAM GROUP)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • had subacute motor incomplete SCI (AIS-C or D),
  • candidate for gait rehabilitation with Lokomat® after cervical or thoracic SCI;
  • stable medical treatment at least one week before and during the study;
  • without limitation of passive range of movement in joints
  • agreed to participate after signing a written informed consent form.

You may not qualify if:

  • unstable clinical state
  • severe spasticity (MAS\>=3)
  • disagreed to sign consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

March 9, 2016

First Posted

March 17, 2016

Study Start

December 1, 2010

Primary Completion

June 1, 2015

Study Completion

August 1, 2015

Last Updated

March 17, 2016

Record last verified: 2016-02